Issues

Home > Issues (Page 9)

April 10, 2022 Innovation, Issues

Nearly 84 million Americans live in “primary-care health professional shortage areas” — places that don’t have enough primary-care physicians to meet patient need. That includes over 7.8 million patients living here in California. Even in the face of this shortage, only 25 states grant the right of “full practice” to nurse practitioners, or NPs, who could immediately address this problem. In the remaining states, “scope-of-practice” laws prevent NPs from evaluating patients, ordering and interpreting diagnostic tests and managing treatments. States with such...

March 24, 2022 Policy Proposals

Last week, the U.S. Senate Finance Committee held a hearing, "Prescription Drug Price Inflation: An Urgent Need to Lower Drug Prices in Medicare." It's rare to see so many falsehoods in so few words. The idea that drug-price inflation is especially bad or that it poses some sort of threat to our health system is at best confused — and at worst dishonest. The hearing was largely intended to give Senate Democrats a forum to grandstand with calls for price controls on prescription drugs. That such...

March 18, 2022 Coronavirus, Issues

The federal public health emergency prompted by the COVID-19 pandemic is set to expire in mid-April. Some states have already let their own emergency declarations lapse. It's about time. COVID-19 is no longer the crisis it was back in 2020. Living in a permanent state of emergency is unsustainable. But that doesn't mean we should go back to the pre-pandemic status quo. Many of the reforms enacted during the state of emergency — especially those that liberalized the healthcare labor market — deserve to...

March 17, 2022 Coronavirus, Issues

It ignores the risk of hazardous drug-drug interactions with the Pfizer pill. As someone who has closely followed and written extensively about the development of COVID-19 vaccines and drug treatments since the beginning of the pandemic, one pronouncement in President Joe Biden's State of the Union speech raised red flags: "We're also ready with antiviral treatments. If you get COVID-19, the Pfizer pill reduces your chances of ending up in the hospital by 90% ...

March 14, 2022 Issues, Price and Costs

As President Biden's recent State of the Union address made clear, drug pricing will remain a top policy issue for the foreseeable future. The president is correct that something must be done, but his proposals are wrongheaded and will only make things worse. Instead of focusing on government price controls, Congress should remove the obstacles limiting patient control and choice. The claim that prices are lower, and quality is higher, when consumers have more choices is typically uncontroversial. Yet, for some reason...

March 8, 2022 Issues, Price and Costs

Popular wisdom is often wrong. Consider, for example, how it views organic agriculture, which has grown to a $48 billion a year industry in the U.S. Organic products are sold at outlets ranging from local farmers' markets to large supermarket chains, and many people assume that there is something more natural, wholesome, or environmentally sustainable about them. None of that is true. What's remarkable about this agriculture sector is that the government's extensive promotion has been a hoax from the beginning, having nothing...

March 8, 2022 Issues, Price and Costs

Late last month, the Federal Trade Commission announced it would seek public comments on the ways pharmacy benefit managers distort the prices of prescription drugs. PBMs deserve the scrutiny, as they're to blame for much of the rise in prescription drug costs. Insurers hire PBMs to negotiate drug prices with manufacturers and determine which medicines end up on a plan's formulary. To guarantee their drug has a spot on the list, pharmaceutical firms routinely offer these gatekeepers deep discounts on medications. Savings on...

March 7, 2022 Issues, Value

In his last blog post before resigning as director of the National Institutes of Health in December 2021, Francis Collins touted many of the important areas of research NIH conducted or funded in his more than 12 years leading the organization, “from innovative immunotherapies for treating cancer to the gift of mRNA vaccines to combat a pandemic.” He could have added to this list other frontiers of medicine explored by NIH-supported researchers: how the human brain works; the health benefits of the trillions of microbes that call our bodies...

March 4, 2022 Coronavirus, Issues

‘Test to Treat’ ignores the significant risk of drug interactions with the Pfizer pill. President Biden touted a new anti-Covid initiative in his State of the Union address Tuesday. “We’re also ready with antiviral treatments. If you get Covid-19, the Pfizer pill reduces your chances of ending up in the hospital by 90%,” he said. “And we’re launching the ‘Test to Treat’ initiative so people can get tested at a pharmacy, and if they’re positive, receive antiviral pills on the spot at no...

March 2, 2022 Innovation, Issues

“That morning I squeezed every orange and it felt like a wet sponge – I knew I lost the whole crop,” said Natalia Derevianko, a small farmer in the tiny Florida town of Archer, somewhere in the void between Orlando and Tallahassee.   Florida’s peninsular climate offers farmers an opportunity to grow high-value fruit crops in the winter months when much of the rest of the country is blanketed in snow. On Jan. 30, this season’s valuable crop of citrus, peaches, and avocados was...

March 1, 2022 Briefs, Policy Proposals, Price and Costs, Studies

READ THE REPORT The problem of drug affordability is caused by the perverse incentives created by the third-party payer system that have disempowered patients in favor of insurers and other supply-chain intermediaries. The insurance flaws have created pricing systems that inequitably transfer a disproportionate share of drug costs on to patients. This arrangement inappropriately imposes a drug affordability problem on patients who require expensive medicines. The insurance flaws also incent benefit design policies that create additional affordability burdens and unnecessarily increase...

February 28, 2022 Issues, Price and Costs

Too often, regulations undermine the competitive process in the name of promoting competition. The ill-conceived Right to Repair legislation exemplify the problems and risks. Under the pretense of promoting competition, states as diverse as Texas and California, Arkansas and Hawaii have all considered bills that would violate medical device companies’ intellectual property rights. While many have been defeated, some legislators seem intent on advancing one businesses interest over another, which undermines competitive efficiency and, in the case of medical devices, creates risks to patient care. At issue are the rules...

February 22, 2022 Blog, Policy Proposals

It’s budget season in Sacramento. Governor Gavin Newsom’s spending proposal is the largest in the Golden State’s history. There’s no shortage of expensive and misguided policies in his budget. Chief among them is his push to expand Medi-Cal, the state’s Medicaid program, to cover all undocumented immigrants. Doing so would make Medi-Cal worse for its legacy beneficiaries and nudge the state closer to the government-run, single-payer system that is the long-term goal of Newsom and his progressive allies. The governor proposes spending...

February 22, 2022 Issues, Multimedia, Policy Proposals

Watch PRI’s Wayne Winegarden, director of our Center for Medical Economics and Innovation, discuss efforts by the Federal Trade Commission to considering ordering large pharmacy benefits managers to study the competitive impact of contractual provisions, reimbursement adjustments, and other practices affecting drug prices on Scripps National News. https://youtu.be/DQsjKM44ScQ...

February 10, 2022 Issues, Price and Costs

Last week, President Joe Biden announced the re-launch of his "Cancer Moonshot" initiative, a project he created in 2016 while serving as Vice President in the Obama administration. The ambitious effort aims to "end cancer as we know it today" by, among other things, halving the death rate from the disease by 2047. That goal is laudable. It will also be impossible to achieve if the president continues to make prescription drug price controls a top administration priority. The only way to spur the...

February 8, 2022 Issues, Price and Costs

According to a new Bureau of Labor Statistics report, consumer prices across a range of goods and services rose 7% between December 2020 and December 2021. It's the largest annual inflation growth in more than 40 years. But the BLS data did reveal one surprising finding. There was zero prescription drug price inflation last year. Yet, as part of their moribund Build Back Better Act, Democrats are continuing to propose price controls on drugs. It makes no sense. Prescription drugs were an outlier in the BLS report....

February 7, 2022 Blog, Industry Trends

Upon facing declining revenue prospects, physicians are shuttering their private, independent practices to partner up with larger hospitals that have near-monopolies on care in the regions they serve. This trend is depressing news for most Americans. Further concentration of market power in these health systems ultimately results in less personalized care and higher overall costs for patients. The effect of the decrease in independent medical practice Medicare physician’s pay has increased by 11% over the past 20 years. The overhead costs of operating an independent medical...